WO2022167925A1 - Association or composition comprising stabilised lactoferrin - Google Patents
Association or composition comprising stabilised lactoferrin Download PDFInfo
- Publication number
- WO2022167925A1 WO2022167925A1 PCT/IB2022/050853 IB2022050853W WO2022167925A1 WO 2022167925 A1 WO2022167925 A1 WO 2022167925A1 IB 2022050853 W IB2022050853 W IB 2022050853W WO 2022167925 A1 WO2022167925 A1 WO 2022167925A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- association
- lactoferrin
- salts
- sialic acid
- anyone
- Prior art date
Links
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 58
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 58
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 58
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 58
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 53
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 28
- 239000005017 polysaccharide Substances 0.000 claims abstract description 28
- 150000004804 polysaccharides Chemical class 0.000 claims description 27
- 208000036142 Viral infection Diseases 0.000 claims description 19
- 230000009385 viral infection Effects 0.000 claims description 19
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 claims description 18
- 229940072440 bovine lactoferrin Drugs 0.000 claims description 18
- WQZGKKKJIJFFOK-UHFFFAOYSA-N hexopyranose Chemical compound OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- -1 zinc salt Chemical class 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- 241000711573 Coronaviridae Species 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical group [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 6
- 239000011686 zinc sulphate Substances 0.000 claims description 6
- 235000009529 zinc sulphate Nutrition 0.000 claims description 6
- 241000709661 Enterovirus Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 150000003751 zinc Chemical class 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- 229920001586 anionic polysaccharide Polymers 0.000 claims description 2
- 150000004836 anionic polysaccharides Chemical class 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 235000013904 zinc acetate Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 241000700605 Viruses Species 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 10
- 238000004925 denaturation Methods 0.000 description 10
- 230000036425 denaturation Effects 0.000 description 10
- 230000000750 progressive effect Effects 0.000 description 10
- 208000025721 COVID-19 Diseases 0.000 description 9
- 238000001142 circular dichroism spectrum Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000012669 liquid formulation Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020005087 unfolded proteins Proteins 0.000 description 6
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 241000315672 SARS coronavirus Species 0.000 description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 102000050459 human LTF Human genes 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101710147732 Small envelope protein Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 108010038047 apolactoferrin Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 102000036068 sialic acid binding proteins Human genes 0.000 description 1
- 108091000315 sialic acid binding proteins Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Definitions
- the present invention relates to the association of lactoferrin,at least one polysaccharide or salts thereof and at least one sialic acid or salts thereof in order to increase the stability of lactoferrin and consequent bioavailability of the same.
- the present invention further relates to pharmaceutically compositions comprising said association and the use thereof.
- SARS-CoV Severe Acute Respiratory Syndrome
- MERS-CoV Middle East Respiratory Syndrome
- the spike protein is located on the virus envelope and promotes the attachment to the host cell and the fusion between the virus and the cellular membrane.
- SARS-CoV-2 is characterised by a single-stranded RNA genome and the expression of four essential structural proteins: a spyke glycoprotein, a small envelope protein, a matrix protein and a nucleocapside protein.
- the spike (S) glycoprotein is composed of two subunits (S1 and S2).
- Homotrimers of S are responsible for binding with high affinity the ACE2 human receptor which is expressed on the surface of pulmonary, cardiac, renal, intestinal and endothelial human cells. In particular, nasal epithelia show the highest ACE2 expression among all investigated cells of the respiratory tree.
- Lactoferrin inhibits SARS-Cov-2 infection (Carlos Alberto Marques de Carvalho et al “In Vitro Inhibition of SARS-Cov-2 infection by bovine lactoferrin BioRix preprint May 132020, Chang et al “Lactogerrin as potential preventive and adjunct treatment for COVID-19” International Journal of Antimicrobial Agents August 52020, Kell et al “The biology of Lactoferrin, an iron-binding protein that can help defend against viruses and bacteria” Frontiers in immunology May 282020) and have proposed the use of Lactoferrin for the prevention and/or treatment of SARS- Cov-2 infections and, more in general, for the prevention and/or treatment of bacterial or viral infections.
- Lactoferrin i.e. bovine lactoferrin (BLf) is an iron-binding glycoprotein folded in two symmetric globular lobes (N- and C-lobes) with antimicrobial and immunomodulatory activities.
- BLf is physiologically present in external secretions, especially in milk.
- BLf has been shown to possess antiviral activity against a broad spectrum of RNA and DNA viruses. These viruses typically utilize common molecules on the cell membrane to facilitate their invasion into cells.
- the sialic acid binding protein hemagglutinin located in the viral envelope (analogous to S1 spike protein in SARS CoV 2), plays a significant role in the early steps of viral infection and represents an attractive target for the development of anti-influenza drugs. It has been demonstrated that lactoferrin interaction with influenza hemagglutinin results in the inhibition of the viral entry process. The authors of the present invention have surprisingly discovered that thermal stability of lactoferrin can be strongly increased when the molecule is combined with at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof thereby increasing the bioavalaibility of said molecule in medical formulations.
- sialic acids appear to have a key role in the infectious pathways of several viruses, including Sars-Cov-2
- the presence of a sialic acid in the formulation can compete with the sialic acid naturally present in the mucin in the aerial ducts, thereby enhancing the entrapment of the virus entering the aerial ducts exerted by the lactoferrin molecule.
- the invention therefore provides a new association comprising lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof that is more stable than lactoferrin alone and that, due to the presence of sialic acid entraps the virus entering the aerial ducts disrupting the ability of the virus to infect the cells.
- the association provided in the present invention when delivered in nosepharyngeal and/or oropharyngeal trait, is a strong weapon in the treatment or in the prevention, or in adjuvating the treatment or the prevention of viral infections, including Sars-Cov-2 infections by entrapping the virus before its penetration and replication into the cell.
- object of the present invention are An association of Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof;
- a composition comprising said association and one or more pharmaceutically/nutraceutically acceptable vehicles and/or diluents and/or excipients and/or additives;
- a composition or the association comprising Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof as defined in the description and in the claims for use in a medical treatment of a viral disease or as an adjuvant in a medical treatment of a viral disease or in the prevention of a viral infection or in a preventive medical treatment against a viral infection comprising the administration of the composition or the association comprising Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof as defined in the description and in the claims to a subject in need thereof;
- a medical device comprising the
- FIG. 1 circular dichroism spectra of native and unfolded blf (bovine lactoferrin) holoprotein in PBS buffer is shown as continuous line together with the thermally unfolded protein (95 °C for 24 hrs) in the same buffer as dashed line.
- the thermally unfolded protein CD spectrum is thus used as a reference for the fully denatured blf.
- the CD spectra recorded during the stability testing are thus considered as a linear combination of the spectra of folded and unfolded protein.
- Figure 2 Thermal denaturation curves of bovine lactoferrin in PBS buffer as a function of time. Protein concentration was 10 mg/mL in PBS buffer pH 7.4.
- Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: ( ⁇ ) 25 °C; ( ⁇ ) 35 °C; and ( ⁇ ) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Figure 3 Thermal denaturation curves of bovine lactoferrin in PBS buffer containing 1% (w/w) sialic acid as a function of time. Protein concentration was 10 mg/mL in PBS buffer pH 7.4. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: ( ⁇ )25 °C; ( ⁇ )35 °C; and ( ⁇ ) 45 °C.
- Continuos lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section.
- Figure 4 Thermal denaturation curves of bovine lactoferrin in PBS buffer containing 1% (w/w) carboxymethylglucan as a function of time. Protein concentration was 10 mg/mL in PBS buffer pH 7.4 and carboxymethylglucan. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: ( ⁇ )25 °C; ( ⁇ )35 °C; and ( ⁇ ) 45 °C. Continuos lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section.
- the present invention relates to an association of Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof.
- the association can additionally comprise at least one zinc salt.
- the association can comprise or consist of Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof in a w/w ratio, respectively, from about 1:1:0.1 to about 1:5:1.
- the w/w ratio Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof is, respectively, from about 1:2:0.1 to about 1:5:1, from about 1:3:0.1 to about 1:5:1; from about 1:4:0.1 to about 1:5:1 or from about 1:5:0.1 to about 1:5:1.
- the association can comprise consist of Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof: zinc salt/s in a w/w ratio, respectively, from about 1:1:0.1:0 to about 1:5:1:0.05.
- the w/w ratio Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof: zinc salt/s is, respectively, from about 1:2:0.1:0 to about 1:5:1:0.05, from about 1:3:0.1:0 to about 1:5:1:0.05; from about 1:4:0.1:0 to about 1:5:1:0.05 or from about 1:5:0.1:0 to about 1:5:1:0.05.
- the weight is referred to the dry weight of each compound.
- the association can be an association comprising or consisting of the following amounts of compounds suspended in sterile water or in another suitable solvent: Lactoferrin from 0.01 to 1 % (from 0.1 to 10 mg/mL) Negatively charged polysaccharide/s or salts thereof from 0.01 to 5 % (from 0.1 to 50 mg/mL) Sialic acid/s or salts thereof from 0.001 to 1 % (from 0.01 to 10 mg/mL) Zinc salt/s comprised from 0 to 0.0005 % (from 0 to 0.005 mg/mL) According to the description the salts of each compound are intended as pharmaceutically or nutraceutically acceptable salts.
- Zinc is known to be an essential element that is crucial for growth, development, and the maintenance of immune function. Its known that zinc status is a critical factor that can influence antiviral immunity, particularly as zinc-deficient populations are often most at risk of acquiring viral infections such as HIV or hepatitis C virus and an abundance of evidence has accumulated over the past 50 y to demonstrate the antiviral activity of zinc against a variety of viruses, and via numerous mechanisms. It has been recently reported that most of the risk groups described for COVID-19 are at the same time groups that were associated with zinc deficiency.
- the association of the invention can advantageously further comprise Zinc, in the form of a suitable salt, due to the antiviral properties of this ion.
- suitable zinc salts can be zinc sulphate, Zn(SO4), zinc acetate, zinc chloride or a mixture thereof.
- lactoferrin can be bovine lactoferrin or recombinantly produced lactoferrin, such as recombinant human lactoferrin.
- Recombinant human lactoferrin can be produced in any way known to the skilled person, e.g. in genetically transformed bacterial, yeast, animal or plant cells according to protocols known in the art.
- dried, lyophilised or spray dried lactoferrin can be used. Due to its easy availability, bovine lactoferrin is preferably used. More than 50 kinds of sialic acid are known, all of which can be obtained from a molecule of neuraminic acid by substituting its amino group or one of its hydroxil groups. In general, the amino group bears either an acetyl or a glycolyl group, but other modifications have been described.
- sialic acid is as defined in formula 1 below, Wherein R 1 is selected from at least one of H, CH 3 , COCH 3 R 2 is selected from at least one of H, OH, CH 3 , CH 2 OH R 3 is selected from at least one of H, OH, CH 3 , CH 2 OH and R 4 is selected from at least one of H, OH, CH 3 , NH COCH 3 as summarised in table 1 below Above are indicated specific possible sialic acids according to the invention.
- suitable polysaccharides are anionic polysaccharides of natural origin, such as polysaccharides extracted from yeasts or from plants or from algae, including polysaccaridic fractions of plant extracts, beta glucanes or salts thereof, carboxy-methyl-glucane or salts thereof, alginates or salts thereof.
- a typical and non-binding example of salts thereof is represented by Na salts thereof.
- polysaccharides of the association of the invention will comprise or consist of carboxy-methyl-glucane or pharmaceutically or nutraceutically acceptable salts thereof.
- the association in any of the embodiments provided in the description and in the claims can be used in a medical treatment of a viral disease or as an adjuvant in a medical treatment of a viral disease or in the prevention of a viral infection.
- the stability of lactoferrin is strongly increased, consequently, the association of the invention is of particular interest for medical use as the active molecule is more stable when associated as described herein rather than alone.
- this association allows obtaining a prolonged shelf-life of lactoferrin, since the molecule is not subjected to degradation or at least the degradation takes place with delayed mode; 3) at productive level, the solubilization of lactoferrin allows using a lower quantity of this molecule in the production of liquid formulations of pharmaceutical specialties, medical devices, dietary supplies, cosmetic products, functional pieces of food, veterinary products; 4) the greater stability of the present lactoferrin formulation allows a better bioavailability thereof.
- said Coronavirus is Sars-Cov-2, MERS- Cov.
- the invention therefore also encompasses a method for the treatment or prevention, or for adjuvating the treatment or the prevention of viral infections caused by a Coronavirus wherein therapeutically effective doses of the association as described hereinabove and in the claims or of the composition as described herein below and in the claims are administered at a therapeutically effective dosage to a subject in need thereof.
- the administration can be repeated several times per die and the association or the composition can be supplied already in the form of single dosages or with a single- dose dispenser.
- Therapeutically effective amount means an amount that is effective in therapy, or an amount sufficient to provide a desired therapeutic effect.
- an amount that is effective in therapy is an amount which produces one or more desired biological activities during the treatment or the prevention of a disease.
- the association of the composition can be vehiculated in the nasopharyngeal and/or in the oropharyngeal trait of the subject treated.
- a further object of the present invention is a composition comprising the association as defined in the description, and in the claims and one or more pharmaceutically/nutraceutically acceptable vehicles and/or diluents and/or excipients and/or additives.
- the sole therapeutically active agent in the composition of the invention is the association as defined in the description and in the claims.
- the composition is the form of a solution, a suspension a spray, a syrup, a tablet, a lozenge, a pill, a candy, a jelly, a granulate (such as an orosoluble granulate), a powder, a cream, an emulsion, a gel, a foam.
- lactoferrin can be suitably dissolved in a liquid formulation comprising the other active components and optionally one or more additional excipient or carrier, immediately before use or after opening the vial containing the liquid formulation comprising the other active ingredients.
- composition can also be provided already aliquoted in single dosages or in single dosage fractions, or can be provided in a dispenser apt to release single dosage or single dosages fractions, such as, by way of example, a dispenser apt to release a pre- defined amount of a solution in the form of a spray.
- Suitable vehicles and/or acceptable diluents and/or excipients are suitable for carrying out the invention although the person skilled in medical composition preparations will know also other suitable vehicles and/or acceptable diluents and/or excipients: - for the liquid formulations, preferably a vehicle comprising: sucrose or sucrose with glycerin and/or mannitol and/or sorbitol, polysorbate 20, PEG, propylene glycol; - for the formulations under suspension and emulsion preferably a vehicle comprising: a natural rubber, agar, sodium alginate, charragenan, pectine, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
- a vehicle comprising one or more diluents such as: lactose, dextrose, sucrose, cellulose, corn starch; one or more lubricants such as: silica, stearic acid, magnesium or calcium stearate, polyethylene glycols; one or more binding agents (agglutinants) such as: starches, mucilages, gelatine, methycellulose, carboxymethylcellulose, or polyvinylpyrrolidone; one or more disaggregating agents such as: starch, alginic acid, alginates or glycolates; effervescent mixtures; desiccants; sweeteners; one or more humectant agents such as: lecithin, polysorbate, lauryl sulphate; known substances, inactive and not toxic from the pharmaceutical/nutraceutic point of view.
- diluents such as: lactose, dextrose, sucrose, cellulose, corn starch
- lubricants such as: silica
- COMPOSITION #1 Bovine Lactoferrin 1 g, Carboxymethylglucan sodium salt, 5 g, Sialic acid, sodium salt, 1 g, polysorbate 80, 0.5 g, propylene glycol, 2 g, Sodium phosphate bibasic, 35 mg, Zinc sulphate, 0,5 mg.
- said viral disease or said viral infection is caused by a Coronavirus as well as other respiratory tract viruses such as rhinovirus, adenovirus, influenza virus etc.
- said Coronavirus is Sars-Cov-2, MERS-Cov as well as other respiratory tract viruses such as rhinovirus, adenovirus, influenza virus etc.
- a further object of the invention relates to a medical device comprising an association or a composition as defined in the description and in the claims.
- said medical device can be an inhaler, a nebuliser or an aerosol delivering device, for nasal and/or buccal drug-delivery.
- the device can be apt to admixing a suitable amount of dry lactoferrin with a suitable amount of a liquid formulation comprising or consisting of the remaining compounds of the association as defined in the description and in the claims and one or more pharmaceutically effective carrier.
- Object of the invention is also a process form manufacturing the composition according to any of the embodiments provided in the present description, comprising the step of formulating the association as defined in any of the embodiments provided in the description and in the claims into suitable dosage units with one or more pharmaceutically/nutraceutically acceptable excipients and/or additives.
- the examples below provide scientific data demonstrating the increased stability of lactoferrin in the association of the invention ad specific and non-limiting examples of the association and of the composition claimed.
- Bovine apolactoferrin and zinc sulphate were obtained from Merck.
- Carboxymethyl glucan was obtained from and sialic acid was obtained from Merck.
- Thermal denaturation experiments were carried out by placing solutions containing 10 mg/mL lactoferrin in sterile, sealed, 1 mL vials and placed in a thermostattable oven at 35 or 45 °C.
- Circular dichroism spectra were measured on a Jasco 650 spectropolarimeter (Jasco Europe srl) equipped with a peltier thermal control unit. Fluorescence spectra were measured on a Shimazu spectrofluorimeter.
- CD spectra were collected on the samples daily or weekly and were deconvoluted according to the method of Chang [. Chang, C. T.; Wu, C. S.; Yang, J. T. Anal Biochem 1978, 91, 13–31.] in order to estimate the % of secondary structures present in solution.
- the 100% native protein was estimated to contain 48% alpha helical content, 28% beta structure and 24% assigned to extended coil.
- Fully denatured protein was considered 100% extend coil, corresponding to the the protein heated at 95 °C of 1 hour and then centrifuged at 10.000 RPM in a eppendorf min centrifuge.
- the amount of secondary structure, as obtained from CD spectra is in fair agreement with threedimensional structure data [https://www.rcsb.org/structure/2HCA, Mir, R., Prem Kumar, R., Ethayathulla, A.S., Singh, N., Sinha, M., Kaur, P., Sharma, S., Singh, T.P. 2006].
- Fig.1 the spectrum of native blf protein in PBS buffer is shown together with the thermally unfolded protein (95 °C for 24 hrs) in the same buffer. The thermally unfolded protein CD spectrum is thus used as a reference for the fully denatured blf.
- the CD spectra recorded during the stability testing are thus considered as a linear combination of the spectra of folded and unfolded protein.
- the denaturation degree Y has been thus established as the fraction of native protein versus the total protein (folded plus unfolded).
- the sterile filtered and sealed blf protein was subjected to a regime of heating as a function of time and CD spectra were recorded at regular intervals.
- the function Y was thus reported as a function of time as described under the methods section.
- Fig.2 represent the protein in PBS buffer at 25, 35 and 45 °C.
- Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: ( ⁇ ) 25 °C; ( ⁇ ) 35 °C; and ( ⁇ ) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1 below. As shown in figure 3, protein concentration was 10 mg/mL in PBS buffer pH 7.4. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: ( ⁇ ) 25 °C; ( ⁇ ) 35 °C; and ( ⁇ ) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the association of lactoferrin, at least one polysaccharide or salts thereof and at least one sialic acid or salts thereof in order to increase the stability of lactoferrin and consequent bioavailability of the same. The present invention further relates to pharmaceutically compositions comprising said association and the use thereof.
Description
ASSOCIATION OR COMPOSITION COMPRISING STABILISED LACTOFERRIN The present invention relates to the association of lactoferrin,at least one polysaccharide or salts thereof and at least one sialic acid or salts thereof in order to increase the stability of lactoferrin and consequent bioavailability of the same. The present invention further relates to pharmaceutically compositions comprising said association and the use thereof. STATE OF THE ART Recent global pandemic caused by SARS-Cov-2 infection has caused up to date more than 29,000,000 infections and more than 900,000 deaths. At present, no vaccine to prevent the infection is available and various treatment protocols are under investigation. SARS-Cov-2 belongs to the Corinaviridae family. To date 7 coronavirus strains are known to infect humans and no approved therapies or vaccine against them are available. In the past two decades, in addition to SARS-CoV-2, two other β-coronavirus have caused three of the most severe epidemics worldwide: SARS-CoV and MERS-CoV which respectively cause the Severe Acute Respiratory Syndrome (SARS), and the Middle East Respiratory Syndrome (MERS). It is well characterized how SARS-CoV infection is mediated by the high-affinity interactions between the receptor-binding domain (RBD) of the spike (S) glycoprotein and the human-host Angiotensin-converting enzyme 2 (ACE2) receptor. The spike protein is located on the virus envelope and promotes the attachment to the host cell and the fusion between the virus and the cellular membrane. SARS-CoV-2 is characterised by a single-stranded RNA genome and the expression of four essential structural proteins: a spyke glycoprotein, a small envelope protein, a matrix protein and a nucleocapside protein. The spike (S) glycoprotein is composed of two subunits (S1 and S2). Homotrimers of S are responsible for binding with high affinity the ACE2 human receptor which is expressed on the surface of pulmonary, cardiac, renal, intestinal and endothelial human cells. In particular, nasal epithelia show the highest ACE2 expression among all investigated cells of the respiratory tree. Most patients infected by SARS-Cov-2 exhibit mild/moderate symptoms, but about 15% develop acute pneumonia and about 5% progress to acute respiratory distress syndrome, septic shock and/or multiple organ failure, associated with high mortality. Recent publications have disclosed that Lactoferrin inhibits SARS-Cov-2 infection (Carlos Alberto Marques de Carvalho et al “In Vitro Inhibition of SARS-Cov-2 infection
by bovine lactoferrin BioRix preprint May 132020, Chang et al “Lactogerrin as potential preventive and adjunct treatment for COVID-19” International Journal of Antimicrobial Agents August 52020, Kell et al “The biology of Lactoferrin, an iron-binding protein that can help defend against viruses and bacteria” Frontiers in immunology May 282020) and have proposed the use of Lactoferrin for the prevention and/or treatment of SARS- Cov-2 infections and, more in general, for the prevention and/or treatment of bacterial or viral infections. Milanetti et al 2020 (Milanetti et al “In-Silico evidence for two receptors based strategy of SARS-CoV-2” Biorix April 2020) have recently that SARS-Cov-2 infection of human airway epithelial cells involves not only high affinity interactions with ACE2 receptor but also low-affinity interactions with sialic acid containing polysaccharides, using a sialic binding region on the spike protein. SUMMARY OF THE INVENTION The authors of the present invention discovered that unlike SARS-CoV but similar to MERS-CoV and influenza A virus, SARS CoV 2 virions, possesses a sialic acid like binding site and possibly interacts with sialic acid containing oligosaccharides. Thus, impairing binding of oligosaccharides could be an important strategy to contrast SARS CoV 2 virus entry into the target cells. Lactoferrin, i.e. bovine lactoferrin (BLf) is an iron-binding glycoprotein folded in two symmetric globular lobes (N- and C-lobes) with antimicrobial and immunomodulatory activities. BLf is physiologically present in external secretions, especially in milk. BLf has been shown to possess antiviral activity against a broad spectrum of RNA and DNA viruses. These viruses typically utilize common molecules on the cell membrane to facilitate their invasion into cells. In the case of influenza virus, the sialic acid binding protein hemagglutinin, located in the viral envelope (analogous to S1 spike protein in SARS CoV 2), plays a significant role in the early steps of viral infection and represents an attractive target for the development of anti-influenza drugs. It has been demonstrated that lactoferrin interaction with influenza hemagglutinin results in the inhibition of the viral entry process. The authors of the present invention have surprisingly discovered that thermal stability of lactoferrin can be strongly increased when the molecule is combined with at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof thereby increasing the bioavalaibility of said molecule in medical formulations. Furthermore, as sialic acids appear to have a key role in the infectious
pathways of several viruses, including Sars-Cov-2, the presence of a sialic acid in the formulation can compete with the sialic acid naturally present in the mucin in the aerial ducts, thereby enhancing the entrapment of the virus entering the aerial ducts exerted by the lactoferrin molecule. The invention therefore provides a new association comprising lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof that is more stable than lactoferrin alone and that, due to the presence of sialic acid entraps the virus entering the aerial ducts disrupting the ability of the virus to infect the cells. In particular, for viruses with an extremely high infectious efficiency, such as Sars-Cov- 2, the association provided in the present invention, when delivered in nosepharyngeal and/or oropharyngeal trait, is a strong weapon in the treatment or in the prevention, or in adjuvating the treatment or the prevention of viral infections, including Sars-Cov-2 infections by entrapping the virus before its penetration and replication into the cell. Therefore, object of the present invention are An association of Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof; A composition comprising said association and one or more pharmaceutically/nutraceutically acceptable vehicles and/or diluents and/or excipients and/or additives; A composition or the association comprising Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof as defined in the description and in the claims for use in a medical treatment of a viral disease or as an adjuvant in a medical treatment of a viral disease or in the prevention of a viral infection or in a preventive medical treatment against a viral infection comprising the administration of the composition or the association comprising Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof as defined in the description and in the claims to a subject in need thereof; A medical device comprising the composition or the association comprising Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof as defined in the description and in the claims suitable for administration thereof in the nosepharyngeal and/or oropharyngeal trait; A process for manufacturing the composition as defined in the description and in the claims wherein an association as defined in the description and in the claims is
formulated into suitable dosage units with one or more pharmaceutically/nutraceutically acceptable excipients and/or additives. GLOSSARY DETAILED DESCRIPTION OF THE FIGURES Figure 1 circular dichroism spectra of native and unfolded blf (bovine lactoferrin) holoprotein in PBS buffer is shown as continuous line together with the thermally unfolded protein (95 °C for 24 hrs) in the same buffer as dashed line. The thermally unfolded protein CD spectrum is thus used as a reference for the fully denatured blf. The CD spectra recorded during the stability testing are thus considered as a linear combination of the spectra of folded and unfolded protein. Figure 2: Thermal denaturation curves of bovine lactoferrin in PBS buffer as a function of time. Protein concentration was 10 mg/mL in PBS buffer pH 7.4. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■) 25 °C; (♦) 35 °C; and (●) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Figure 3 Thermal denaturation curves of bovine lactoferrin in PBS buffer containing 1% (w/w) sialic acid as a function of time. Protein concentration was 10 mg/mL in PBS buffer pH 7.4. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■)25 °C; (♦)35 °C; and (●) 45 °C. Continuos lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Figure 4 Thermal denaturation curves of bovine lactoferrin in PBS buffer containing 1% (w/w) carboxymethylglucan as a function of time. Protein concentration was 10 mg/mL in PBS buffer pH 7.4 and carboxymethylglucan. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■)25 °C; (♦)35 °C; and (●) 45 °C. Continuos lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Figure 5, Thermal denaturation curves of bovine lactoferrin in PBS buffer containing 1% (w/w) carboxymethylglucan and 1 % sialic acid as a function of time.
Protein concentration was 10 mg/mL in PBS buffer pH 7.4 containing sialic acid (1%) and carboxymethylglucan (1%). Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■)25 °C; (♦)35 °C; and (●) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1. Figure 6 Thermal denaturation curves of bovine lactoferrin in PBS buffer containing 5% (w/w) carboxymethylglucan and 1 % sialic acid as a function of time. Protein concentration was 10 mg/mL in PBS buffer pH 7.4 containing sialic acid (1%) and carboxymethylglucan (5%). Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■)25 °C; (♦)35 °C; and (●) 45 °C. Continuos lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an association of Lactoferrin, at least one negatively charged polysaccharide or salts thereof and at least one sialic acid or salts thereof. The association can additionally comprise at least one zinc salt. In an embodiment of the invention, the association can comprise or consist of Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof in a w/w ratio, respectively, from about 1:1:0.1 to about 1:5:1. In an embodiment, the w/w ratio Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof is, respectively, from about 1:2:0.1 to about 1:5:1, from about 1:3:0.1 to about 1:5:1; from about 1:4:0.1 to about 1:5:1 or from about 1:5:0.1 to about 1:5:1. In a further embodiment, the association can comprise consist of Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof: zinc salt/s in a w/w ratio, respectively, from about 1:1:0.1:0 to about 1:5:1:0.05. In an embodiment, the w/w ratio Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof: zinc salt/s is, respectively, from about 1:2:0.1:0 to about 1:5:1:0.05, from about 1:3:0.1:0 to about 1:5:1:0.05; from about 1:4:0.1:0 to about 1:5:1:0.05 or from about 1:5:0.1:0 to about 1:5:1:0.05. The weight is referred to the dry weight of each compound.
By way of example, the association can be an association comprising or consisting of the following amounts of compounds suspended in sterile water or in another suitable solvent: Lactoferrin from 0.01 to 1 % (from 0.1 to 10 mg/mL) Negatively charged polysaccharide/s or salts thereof from 0.01 to 5 % (from 0.1 to 50 mg/mL) Sialic acid/s or salts thereof from 0.001 to 1 % (from 0.01 to 10 mg/mL) Zinc salt/s comprised from 0 to 0.0005 % (from 0 to 0.005 mg/mL) According to the description the salts of each compound are intended as pharmaceutically or nutraceutically acceptable salts. Zinc is known to be an essential element that is crucial for growth, development, and the maintenance of immune function. Its known that zinc status is a critical factor that can influence antiviral immunity, particularly as zinc-deficient populations are often most at risk of acquiring viral infections such as HIV or hepatitis C virus and an abundance of evidence has accumulated over the past 50 y to demonstrate the antiviral activity of zinc against a variety of viruses, and via numerous mechanisms. It has been recently reported that most of the risk groups described for COVID-19 are at the same time groups that were associated with zinc deficiency. As zinc is essential to preserve natural tissue barriers such as the respiratory epithelium, preventing pathogen entry, for a balanced function of the immune system and the redox system, zinc deficiency can probably be added to the factors predisposing individuals to infection and detrimental progression of COVID-19. Therefore, the association of the invention can advantageously further comprise Zinc, in the form of a suitable salt, due to the antiviral properties of this ion. According to the invention, suitable zinc salts can be zinc sulphate, Zn(SO4), zinc acetate, zinc chloride or a mixture thereof. According to the invention, lactoferrin can be bovine lactoferrin or recombinantly produced lactoferrin, such as recombinant human lactoferrin. Recombinant human lactoferrin can be produced in any way known to the skilled person, e.g. in genetically transformed bacterial, yeast, animal or plant cells according to protocols known in the art. In a preferred embodiment, dried, lyophilised or spray dried lactoferrin can be used. Due to its easy availability, bovine lactoferrin is preferably used. More than 50 kinds of sialic acid are known, all of which can be obtained from a molecule of neuraminic acid by substituting its amino group or one of its hydroxil groups. In general, the amino group bears either an acetyl or a glycolyl group, but other modifications have been described.
Although any sialic acid is suitable for the present invention, in a preferred embodiment the sialic acid is as defined in formula 1 below,
Wherein R1 is selected from at least one of H, CH3, COCH3 R2 is selected from at least one of H, OH, CH3, CH2OH R3 is selected from at least one of H, OH, CH3, CH2OH and R4 is selected from at least one of H, OH, CH3, NH COCH3 as summarised in table 1 below
Above are indicated specific possible sialic acids according to the invention.
According to the invention, suitable polysaccharides are anionic polysaccharides of natural origin, such as polysaccharides extracted from yeasts or from plants or from algae, including polysaccaridic fractions of plant extracts, beta glucanes or salts thereof, carboxy-methyl-glucane or salts thereof, alginates or salts thereof. A typical and non-binding example of salts thereof is represented by Na salts thereof. In a preferred embodiment polysaccharides of the association of the invention will comprise or consist of carboxy-methyl-glucane or pharmaceutically or nutraceutically acceptable salts thereof. Due to the protective effect against viral infection exerted by lactoferrin, the association in any of the embodiments provided in the description and in the claims, can be used in a medical treatment of a viral disease or as an adjuvant in a medical treatment of a viral disease or in the prevention of a viral infection. As indicated in the examples below, following the association with at least one polysaccharide and at least one sialic acid as disclosed in the present description, the stability of lactoferrin is strongly increased, consequently, the association of the invention is of particular interest for medical use as the active molecule is more stable when associated as described herein rather than alone. Therefore, among the advantages of the association according to the present invention are the following ones: 1) the solubilisation of lactoferrin and the stabilization thereof, in particular in aqueous solution; 2) the greater thermal stability of lactoferrin in solution constituted an advantage from the industrial point of view for the production of liquid formulations. In fact, this association allows obtaining a prolonged shelf-life of lactoferrin, since the molecule is not subjected to degradation or at least the degradation takes place with delayed mode; 3) at productive level, the solubilization of lactoferrin allows using a lower quantity of this molecule in the production of liquid formulations of pharmaceutical specialties, medical devices, dietary supplies, cosmetic products, functional pieces of food, veterinary products; 4) the greater stability of the present lactoferrin formulation allows a better bioavailability thereof. So far, higher concentrations of this molecule are reached at the tissue level in presence of at least one polysaccharide and at least one sialic acid with respect to the administration of sole lactoferrin, with consequent increase in efficiency;
5) given that polysaccharides and sialic acids make lactoferrin more bioavailable and consequently more effective, it strengthens even the possible synergic effects between lactoferrin and other molecules. Due to the reported role of lactoferrin and sialic acid in Coronaviruses infections, the association of the invention is of particular interest when used in the treatment or prevention, or in adjuvating the treatment or the prevention of viral infections caused by a Coronavirus, rhinovirus, adenovirus, influenza virus. In a preferred embodiment of the inventions, said Coronavirus is Sars-Cov-2, MERS- Cov. The invention therefore also encompasses a method for the treatment or prevention, or for adjuvating the treatment or the prevention of viral infections caused by a Coronavirus wherein therapeutically effective doses of the association as described hereinabove and in the claims or of the composition as described herein below and in the claims are administered at a therapeutically effective dosage to a subject in need thereof. The administration can be repeated several times per die and the association or the composition can be supplied already in the form of single dosages or with a single- dose dispenser. Therapeutically effective amount means an amount that is effective in therapy, or an amount sufficient to provide a desired therapeutic effect. An amount that is effective in therapy is an amount which produces one or more desired biological activities during the treatment or the prevention of a disease. In the present case during the treatment or the prevention of a viral infectious disease as defined herein. According to the invention, the association of the composition can be vehiculated in the nasopharyngeal and/or in the oropharyngeal trait of the subject treated. A further object of the present invention is a composition comprising the association as defined in the description, and in the claims and one or more pharmaceutically/nutraceutically acceptable vehicles and/or diluents and/or excipients and/or additives. According to one embodiment of the invention, the sole therapeutically active agent in the composition of the invention is the association as defined in the description and in the claims. In an embodiment of the present invention, the composition is the form of a solution, a suspension a spray, a syrup, a tablet, a lozenge, a pill, a candy, a jelly, a granulate (such as an orosoluble granulate), a powder, a cream, an emulsion, a gel, a foam.
When the composition is in liquid form, lactoferrin can be suitably dissolved in a liquid formulation comprising the other active components and optionally one or more additional excipient or carrier, immediately before use or after opening the vial containing the liquid formulation comprising the other active ingredients. The composition can also be provided already aliquoted in single dosages or in single dosage fractions, or can be provided in a dispenser apt to release single dosage or single dosages fractions, such as, by way of example, a dispenser apt to release a pre- defined amount of a solution in the form of a spray. Among the vehicles and/or acceptable diluents and/or excipients, according to the administration route and the practice of the pharmaceutical/nutritional standards the following are suitable for carrying out the invention although the person skilled in medical composition preparations will know also other suitable vehicles and/or acceptable diluents and/or excipients: - for the liquid formulations, preferably a vehicle comprising: sucrose or sucrose with glycerin and/or mannitol and/or sorbitol, polysorbate 20, PEG, propylene glycol; - for the formulations under suspension and emulsion preferably a vehicle comprising: a natural rubber, agar, sodium alginate, charragenan, pectine, methylcellulose, carboxymethylcellulose or polyvinyl alcohol. - for the solid formulations preferably a vehicle comprising one or more diluents such as: lactose, dextrose, sucrose, cellulose, corn starch; one or more lubricants such as: silica, stearic acid, magnesium or calcium stearate, polyethylene glycols; one or more binding agents (agglutinants) such as: starches, mucilages, gelatine, methycellulose, carboxymethylcellulose, or polyvinylpyrrolidone; one or more disaggregating agents such as: starch, alginic acid, alginates or glycolates; effervescent mixtures; desiccants; sweeteners; one or more humectant agents such as: lecithin, polysorbate, lauryl sulphate; known substances, inactive and not toxic from the pharmaceutical/nutraceutic point of view. The vehiculants, diluents and excipients mentioned above are meant exclusively by way of example, however not constituting an exhaustive list. Provided herein below are examples of the composition according to the invention. The skilled person, based on the present description, will be able to prepare other compositions by adding to the association of the invention suitable formulative compounds known in the field depending on the desired composition form. COMPOSITION EXAMPLES Composition: Nasal spray: 100 g cont.:
COMPOSITION #1 Bovine Lactoferrin, 1 g, Carboxymethylglucan sodium salt, 5 g, Sialic acid, sodium salt, 1 g, polysorbate 80, 0.5 g, propylene glycol, 2 g, Sodium phosphate bibasic, 35 mg, Zinc sulphate, 0,5 mg. Benzalkoniumchlorid 10 mg, Camphor, 0.1 mg, Eucaliptol 0.2 mg and purified water up to 100 g. COMPOSITION #2 Bovine Lactoferrin, 600 mg, Charragenan, 200 mg, Carboxymethylglucan sodium salt, 2,8 g, Sialic acid, sodium salt, 600 mg, potassium sorbate, 0.5 g, propylene glycol, 2 g, , Sodium phosphate bibasic, 35 mg, Zinc sulphate, 0,03 mg. Benzalkoniumchlorid 10 mg, Camphor, 0.1 mg, Xilitol 0.2 mg and purified water up to 100 g. COMPOSITION #3 Bovine Lactoferrin, 100 mg, Carboxymethylglucan sodium salt, 500 mg, Sialic acid, sodium salt, 100 mg, potassium sorbate, 0.5 g, propylene glycol, 2 g, , Sodium phosphate bibasic, 35 mg, Zinc sulphate, 0,005 mg. Chlorexidine gluconate 10 mg, Phyllantus emblica extract, 0.2 mg and purified water up to 100 g According to the invention, for the reasons provided above with reference to the association, the composition according any of the embodiments provided in the description or in the claims is useful in a medical treatment of a viral disease or as and adjuvant in a medical treatment of a viral disease or in the prevention of a viral infection. Accordingly, in a preferred embodiment, said viral disease or said viral infection is caused by a Coronavirus as well as other respiratory tract viruses such as rhinovirus, adenovirus, influenza virus etc.. In a further preferred embodiment said Coronavirus is Sars-Cov-2, MERS-Cov as well as other respiratory tract viruses such as rhinovirus, adenovirus, influenza virus etc. A further object of the invention relates to a medical device comprising an association or a composition as defined in the description and in the claims. According to an embodiment of the invention, said medical device can be an inhaler, a nebuliser or an aerosol delivering device, for nasal and/or buccal drug-delivery. In one embodiment, the device can be apt to admixing a suitable amount of dry lactoferrin with a suitable amount of a liquid formulation comprising or consisting of the remaining compounds of the association as defined in the description and in the claims and one or more pharmaceutically effective carrier.
Object of the invention is also a process form manufacturing the composition according to any of the embodiments provided in the present description, comprising the step of formulating the association as defined in any of the embodiments provided in the description and in the claims into suitable dosage units with one or more pharmaceutically/nutraceutically acceptable excipients and/or additives. The examples below provide scientific data demonstrating the increased stability of lactoferrin in the association of the invention ad specific and non-limiting examples of the association and of the composition claimed. EXAMPLES Materials and Methods Bovine apolactoferrin and zinc sulphate were obtained from Merck. Carboxymethyl glucan was obtained from and sialic acid was obtained from Merck. Thermal denaturation experiments were carried out by placing solutions containing 10 mg/mL lactoferrin in sterile, sealed, 1 mL vials and placed in a thermostattable oven at 35 or 45 °C. Circular dichroism spectra were measured on a Jasco 650 spectropolarimeter (Jasco Europe srl) equipped with a peltier thermal control unit. Fluorescence spectra were measured on a Shimazu spectrofluorimeter. CD spectra were collected on the samples daily or weekly and were deconvoluted according to the method of Chang [. Chang, C. T.; Wu, C. S.; Yang, J. T. Anal Biochem 1978, 91, 13–31.] in order to estimate the % of secondary structures present in solution. The 100% native protein was estimated to contain 48% alpha helical content, 28% beta structure and 24% assigned to extended coil. Fully denatured protein was considered 100% extend coil, corresponding to the the protein heated at 95 °C of 1 hour and then centrifuged at 10.000 RPM in a eppendorf min centrifuge. The degradation pattern of the product, assuming that it degrades via a first-order reaction, can be described by a simple exponential decay as follows: Y = exp(-kT) [1] Where Y represents the fraction of native protein with respect to the total protein, k is a first order kinetic constant in days-1, The observed result (Y) from each lot has has been fitted to the single exponential [1]l by the least squares method using the Matlab program (Mathworks Inc. Natick, Ma, US)
RESULTS The blf holoprotein native state has been interpreted as the one having a 48% alpha helical content, 28% beta structure and 24% assigned to extended coil. The amount of secondary structure, as obtained from CD spectra (see Fig.1) is in fair agreement with threedimensional structure data [https://www.rcsb.org/structure/2HCA, Mir, R., Prem Kumar, R., Ethayathulla, A.S., Singh, N., Sinha, M., Kaur, P., Sharma, S., Singh, T.P. 2006]. In Fig.1, the spectrum of native blf protein in PBS buffer is shown together with the thermally unfolded protein (95 °C for 24 hrs) in the same buffer. The thermally unfolded protein CD spectrum is thus used as a reference for the fully denatured blf. The CD spectra recorded during the stability testing are thus considered as a linear combination of the spectra of folded and unfolded protein. The denaturation degree Y has been thus established as the fraction of native protein versus the total protein (folded plus unfolded). Thus, the sterile filtered and sealed blf protein was subjected to a regime of heating as a function of time and CD spectra were recorded at regular intervals. The function Y was thus reported as a function of time as described under the methods section. Fig.2 represent the protein in PBS buffer at 25, 35 and 45 °C. Thermal denaturation curves as a function of time of bovine lactoferrin in PBS buffer containing 1% (w/w) sialic acid or carboxymethyl glucan (1% or 5 %) as a function of time are represented in figure 2-6. The data relative to the kinetics of protein denaturation at different temperatures were thus fitted to a single exponential decay and resumed in TABLE I. Values of the first order kinetic constants indicated that (t1/2 = ln(2)/k) the shelf life (half time for denaturation) of the lactoferrin formulations varied from a minimum of 69 days in plain buffer at 45 °C to a maximum of 368 days in the presence of Carboxymethyl glucan and sialic acid. It must be mentioned that at a temperature of 45 °C or higher (not reported) yellowish color accompanied by ammonium release is observed in the presence of sialic acid after 4-5 weeks. Control experiments on plain sialic acid solutions demonstrated that the effect is due to the co-presence of sialic acid and lactoferrin pointing to partial degradation of sialic acid at T ≥ 45 °C. Under recommended storage temperature of 25±3 °C, a clear increase in lactoferrin secondary structure stability is observed in the presence of at least 1% CMG or 1%
sialic acid. Combined presence of sialic acid and CMG each at 1% concentration offers only a modest increase in stability (Fig.5 and 6). As shown in figure 2, protein concentration was 10 mg/mL in PBS buffer pH 7.4. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■) 25 °C; (♦) 35 °C; and (●) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1 below. As shown in figure 3, protein concentration was 10 mg/mL in PBS buffer pH 7.4. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■) 25 °C; (♦) 35 °C; and (●) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1 below. As shown in figure 4, protein concentration was 10 mg/mL in PBS buffer pH 7.4 and 1% carboxymethylglucan. Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■) 25 °C; (♦) 35 °C; and (●) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1. As shown in figure 5, protein concentration was 10 mg/mL in PBS buffer pH 7.4 containing sialic acid (1%) and carboxymethylglucan (1%). Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■) 25 °C; (♦) 35 °C; and (●) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1. As shown in figure 6 protein concentration was 10 mg/mL in PBS buffer pH 7.4 containing sialic acid (1%) and carboxymethylglucan (5%). Kinetic data points have been acquired by UV-CD spectroscopy thus considering the progressive loss of secondary structure. Temperatures were: (■)25 °C; (♦)35 °C; and (●) 45 °C. Continuous lines have been obtained by least squares fitting of the data to the simple exponential decay described in material section. Values are summarized in Table 1.
TABLE 1 Results of data fitting relative to Figs.2-6.
Kinetic constant k can be obtained in days-1 from the relationship k = ln(2) / t1/2 As clear from the data obtained, the association of the invention strongly increases the stability of lactoferrin at temperatures from 25 to 45°C. In particular, a 6-8 fold increase in the thermal stability of lactoferrin is observed in the presence of at least 1 % carboxymethyl glucan, with a modest increase in stability up to 5% carboxymethyl glucan. Sialic acid at 1% concentration yields a 2-3 fold increase in stability but its concentration cannot be increased due to ammonium release at higher temperature. Mixing sialic acid with carboxymethylglucane provides t1/2 values that are comparable, or slightly higher, to those observed in the presence of carboxymethylglucane alone. In conclusion, effects of carboxymethyl glucane and sialic acid on lactoferrin thermal stability are synergic though not additive, and increase of carboxymethylglucane concentration above 1% has only modest effects on lactoferrin overall stability.
Claims
CLAIMS 1. An association comprising Lactoferrin, at least one negatively charged polysaccharide or salt thereof and at least one sialic acid or salt thereof and optionally a zinc salt.
2. The association according to claim 1 comprising Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof in a w/w ratio, respectively, from about 1:1:0.1 to about 1:5:1.
3. The association according to claim 1 or 2 comprising Lactoferrin: negatively charged polysaccharide/s or salts thereof: sialic acid/s or salts thereof: zinc salt/s in a w/w ratio, respectively, from about 1:1:0.1:0 to about 1:5:1:0.05.
4. The association according to anyone of claims 1 to 3 comprising Lactoferrin from 0.01 to 1 % Negatively charged polysaccharide/s or salts thereof from 0.05 to 5 % Sialic acid/s or salts thereof from 0.001 to 1 % Zinc salt/s comprised from 0 to 0.0005 % up to 100% of distilled water or any other suitable solvent.
5. The association according to any one of claims 1 to 4wherein said zinc salt is zinc sulphate, zinc acetate, zinc chloride or a mixture thereof
6. The association according to claim 5 wherein said zinc salt is Zn(SO4).
7. The association according to any one of claims 1 to 6 wherein said lactoferrin is Bovine lactoferrin or human recombinant lactoferrin.
8. The association according to any one of claims 1 to 7 wherein said lactoferrin is spray dried lactoferrin.
9. The association according to any one of claims 1 to 6 wherein said sialic acid is of formula
Wherein
R1 is selected from at least one of H, CH3, COCH3 R2 is selected from at least one of H, OH, CH3, CH2OH R3 is selected from at least one of H, OH, CH3, CH2OH and R4 is selected from at least one of H, OH, CH3, NH COCH3.
10. The association according to anyone of claims 1 to 9 wherein said polysaccharide is selected from: anionic polysaccharides of natural origin, polysaccharides extracted from yeasts or from plants, polysaccharides extracted from algae, polysaccaridic fractions of plant, yeast or algae extracts, beta glucanes, carboxy-methyl-glucan, alginates.
11. The association according to anyone of claims 1 to 10 for use in the treatment of a viral infection or as adjuvant in a treatment of a viral infection or in a treatment for the prevention of a viral infection.
12. The association for use according to claim 11 wherein said infection is caused by Coronavirus rhinovirus, adenovirus, influenza virus.
13. The association for use according to claim 12 wherein said Coronavirus is Sars- Cov-2 or MERS-Cov.
14 A composition comprising the association as defined in anyone of claims 1 to 10 and one or more pharmaceutically/nutraceutically acceptable vehicle and/or diluent and/or excipient and/or additive.
15. The composition according to claim 14 wherein said composition is in the form of a solution, a suspension, a spray, a syrup, a tablet, a lozenge, a pill, a candy, a jelly, a granulate, a powder, a cream, an emulsion, a gel, a foam.
16. The composition according to claim 15 wherein said excipient is a mucoadhesive excipient.
17. The composition according to claim 16 wherein said mucoadhesive excipient is one or more of, chitosan, hyaluronic acid, resin, gelatin, polyacrylates, cyclodextrins and silicones.
18. The composition according to anyone of claims 14 to 17 for use in the treatment of a viral infection or as adjuvant in a treatment of a viral infection or in a treatment for the prevention of a viral infection.
19. The association for use according to claim 18 wherein said viral disease or said viral infection is caused by a Coronavirus. rhinovirus, adenovirus, influenza virus.
20. The association for use according to claim 19 wherein said Coronavirus is Sars- Cov-2, MERS-Cov.
21. A medical device comprising an association as defined in anyone of claims 1 to 12 or a composition as defined in anyone of claims 14 to 19.
22. The medical device according to claim 21 wherein said medical device is a device apt to nasal and/or buccal drug-delivery.
23. A process form manufacturing the composition according to anyone of claims 14 to 17 wherein the association as defined in anyone of claims 1 to 10 is formulated into suitable dosage units with one or more pharmaceutically/nutraceutically acceptable vehicle and/or diluent and/or excipient and/or additive.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102021000002471A IT202100002471A1 (en) | 2021-02-04 | 2021-02-04 | ASSOCIATION OR COMPOSITION COMPRISING STABILIZED LACTOFERRIN |
IT102021000002471 | 2021-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022167925A1 true WO2022167925A1 (en) | 2022-08-11 |
Family
ID=75539794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/050853 WO2022167925A1 (en) | 2021-02-04 | 2022-02-01 | Association or composition comprising stabilised lactoferrin |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT202100002471A1 (en) |
WO (1) | WO2022167925A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116440068A (en) * | 2023-05-17 | 2023-07-18 | 普迪特(泰州)生物科技有限公司 | Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2674155A1 (en) * | 2012-06-13 | 2013-12-18 | Noos S.r.l. | Association of resveratrol and carboxymethylglucan |
CN111184072A (en) * | 2020-03-02 | 2020-05-22 | 上海育博营养食品有限公司 | Milk powder beneficial to enhancing immunity and improving resistance and production method thereof |
CN111481560A (en) * | 2020-04-23 | 2020-08-04 | 菌维他(北京)医疗科技有限公司 | Application of sialic acid and derivatives in preparing medicine for preventing and treating coronavirus diseases |
CN111990461A (en) * | 2020-08-18 | 2020-11-27 | 北安宜品努卡乳业有限公司 | Mixed milk powder for enhancing immunity and preparation method thereof |
-
2021
- 2021-02-04 IT IT102021000002471A patent/IT202100002471A1/en unknown
-
2022
- 2022-02-01 WO PCT/IB2022/050853 patent/WO2022167925A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2674155A1 (en) * | 2012-06-13 | 2013-12-18 | Noos S.r.l. | Association of resveratrol and carboxymethylglucan |
CN111184072A (en) * | 2020-03-02 | 2020-05-22 | 上海育博营养食品有限公司 | Milk powder beneficial to enhancing immunity and improving resistance and production method thereof |
CN111481560A (en) * | 2020-04-23 | 2020-08-04 | 菌维他(北京)医疗科技有限公司 | Application of sialic acid and derivatives in preparing medicine for preventing and treating coronavirus diseases |
CN111990461A (en) * | 2020-08-18 | 2020-11-27 | 北安宜品努卡乳业有限公司 | Mixed milk powder for enhancing immunity and preparation method thereof |
Non-Patent Citations (6)
Title |
---|
CHANG ET AL.: "Lactogerrin as potential preventive and adjunct treatment for COVID-19", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 5 August 2020 (2020-08-05) |
CHANG RAYMOND ET AL: "Lactoferrin as potential preventative and adjunct treatment for COVID-19", vol. 56, no. 3, 1 September 2020 (2020-09-01), AMSTERDAM, NL, pages 106118, XP055809546, ISSN: 0924-8579, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390755/pdf/main.pdf> DOI: 10.1016/j.ijantimicag.2020.106118 * |
CHANG, C. T.WU, C. S.YANG, J. T., ANAL BIOCHEM, vol. 91, 1978, pages 13 - 31 |
CHEN XIANGYAN ET AL: "Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 164, 14 July 2020 (2020-07-14), pages 331 - 343, XP086335562, ISSN: 0141-8130, [retrieved on 20200714], DOI: 10.1016/J.IJBIOMAC.2020.07.106 * |
KELL ET AL.: "The biology of Lactoferrin, an iron-binding protein that can help defend against viruses and bacteria", FRONTIERS IN IMMUNOLOGY, 28 May 2020 (2020-05-28) |
LI QUANYANG ET AL: "Protection effect of sodium alginate against heat-induced structural changes of lactoferrin molecules at neutral pH", vol. 99, 9 October 2018 (2018-10-09), United Kingdom, pages 513 - 518, XP055841075, ISSN: 0023-6438, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0023643818308569/pdfft?md5=5d9f62995d4a18710eca997628563027&pid=1-s2.0-S0023643818308569-main.pdf> DOI: 10.1016/j.lwt.2018.10.019 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116440068A (en) * | 2023-05-17 | 2023-07-18 | 普迪特(泰州)生物科技有限公司 | Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof |
CN116440068B (en) * | 2023-05-17 | 2023-10-17 | 江苏亨瑞生物医药科技有限公司 | Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
IT202100002471A1 (en) | 2022-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7458438B2 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
JP6952379B2 (en) | Nasal pharmaceutical composition for the treatment of acute viral respiratory illness | |
CN111529685A (en) | Nasal spray preparation for resisting respiratory virus infection | |
CN102439153A (en) | Compositions for stimulation of mammalian innate immune resistance to pathogens | |
US20170360815A1 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
AU2018271873B2 (en) | Glycopeptide derivative compounds and uses thereof | |
KR20210141546A (en) | Stable bacterial extract manufacturing process and use thereof as a medicament | |
JP6837700B2 (en) | How to use dipivefrine | |
WO2021160982A1 (en) | Compositions and applications thereof | |
CN107412747B (en) | A kind of compound preparation containing lactoferrin and sialic acid | |
WO2022167925A1 (en) | Association or composition comprising stabilised lactoferrin | |
CN115282259A (en) | Oral spray preparation based on virus blocking agent and application thereof | |
WO2012103802A1 (en) | Liquid medicinal composition containing echinocandin antifungal agent micafungin | |
Coccolini et al. | Biomedical and nutritional applications of lactoferrin | |
EP4009954A1 (en) | Methods for increasing the bioavailability of otc and pharmaceutical drugs | |
CN114599386A (en) | Compositions and synergistic methods for treating infections | |
CN115209954B (en) | Composition for treating respiratory lesions | |
WO2021191904A1 (en) | Methods for preventing and treating viral infection | |
US20210299077A1 (en) | Liposomal reduced glutathione (lrg) in combination with ivermectin for the treatment of covid-19 | |
CN112638414A (en) | Novel immunomodulatory small molecules | |
RU2773149C2 (en) | Compositions and methods for protection against pathogens and irritants present in air | |
US20220047614A1 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
RU2790223C2 (en) | Compositions and methods for protection from air-suspended pathogens and irritants | |
WO2024096743A1 (en) | Sars-cov-2 binding antibody | |
EP4167989A1 (en) | Composition for treating viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22702055 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22702055 Country of ref document: EP Kind code of ref document: A1 |